EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

AtriCure, Inc. (ATRC) fair value: what the stock is really worth

As of Sep 29, 2026: fair value of AtriCure, Inc. $20.85, price $58.05, upside -64.1%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US04963C2098

AI AtriCure, Inc. logo Some data Sep 27, 2026

AtriCure, Inc.

ATRC · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $20.85 · Strongly overvalued (−64.1%)
✓Quality 69/100
!Mixed Growth (revenue 5y +20.9 %/yr)
!Thin margins · 1.9% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (2/14)
!Narrow moat 41/100
!Evidence only medium, so the estimate is less certain
!Weak on past: 9 out of 100
Watch AtriCure, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$87.14 $19.86 Fair Value $20.85 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $19.86 – $87.14 · fair‑value band $13.31 – $35.07 · the $58.05 price screens above the $20.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 27, 2026.

Follow AtriCure in your weekly email

Every Wednesday you see whether AtriCure is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.

Show more

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Stock analysis

AtriCure, Inc. (ATRC) currently trades at $58.05, while our model-based Fair Value estimate is $20.85, 64.1% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $24.26 per share, and 0 of the 11 models we run sit above the $58.05 price.

Bear case: the Asset-Based group reads lowest at $6.48, and 11 of the 11 models stay below the price. Evidence for this calculation is medium.

Scenario range: $13.31 (bear) to $35.07 (bull), the price of $58.05 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

AtriCure, Inc. reported revenue of $535M in FY2025 versus $274M in FY2021, a compound +18.1%/yr. Reported net income was −$11.4M in FY2025.

Key figures

Market cap $2.8B · P/E ratio 276.4 · P/S ratio 3.96 · EPS (TTM) $0.2100 · Net margin −2.1% · Return on equity 2.2% · Return on assets (EBIT) −2.0% · Operating margin 6.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).

What moves the price

The share trades about 4% below its 52-week high and 124% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −38% fair-value upside, at −64%, ATRC screens richer than that median.

Fair Value models

Bear $13.31 Fair Value $20.85 Bull $35.07
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1571 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $18.63 $27.56 $55.40 76
Owner Earnings $3.44 $5.10 $8.46 75
5Y EBITDA Exit $9.41 $12.91 $19.69 75
All 11 models by family
DCF Models
FCF DCF $18.63 $27.56 $55.40 76
Owner Earnings $3.44 $5.10 $8.46 75
5Y Revenue Exit $13.64 $21.46 $37.77 70
5Y EBITDA Exit $9.41 $12.91 $19.69 75
10Y Revenue Exit $14.94 $28.79 $37.12 67
10Y EBITDA Exit $12.30 $19.89 $31.54 67
Multiples
EV/EBITDA $5.60 $6.78 $7.95 67
EV/Revenue $10.71 $14.42 $18.12 54
Asset-Based
NCAV (Graham) $4.84 $6.48 $9.67 54
Growth DCF
Growth DCF $17.62 $30.02 $54.28 75
Rev-Margin DCF $14.11 $24.26 $44.08 70

Open the full fair value analysis →

Notify me when ATRC reaches fair value

Put ATRC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 69/100

Of which business quality 68 · Market factors (momentum, volatility) 78

Profitability 37
Margins and returns on capital today
Quality Growth 78
Are margins and returns improving?
Cashflow 58
Earnings quality: real cash, not paper profit
Fin. Strength 95
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 38
Calm price path (market factor)
Momentum 95
Price trend over the last 3–12 months (market factor)
52W Momentum 96
Distance to the 52-week high (market factor)
Net Issuance 66
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
Start year 2020 (pandemic). Over 10 years: +15.2% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21.4% (2020) → −0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +27.6% a year for the price and +8.3% for the forecasts.
Forecast 2026 (sales)+13.4%
Forecast 2027 (sales)+12.1%
Projected 2028 (sales)+10.8%
Projected 2029 (sales)+9.6%
Projected 2030 (sales)+8.3%

ATRC screens overvalued: fair value 64% below the price. Compare with Intuitive Surgical, Inc →

Compare AtriCure, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 200 stocks

Beats the industry median on 2/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 69 · Top 25%
Fair Value upside −64.1% · Bottom 25%
Profitability
Return on equity (TTM) 2.2% · Below median
Return on assets 1.3% · Below median
Net margin (TTM) 1.9% · Below median
Operating margin (TTM) 6.3% · Below median
Growth and dividend
Revenue growth 12.8% · Above median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 276.4× · Priciest 25%
P/B 5.63× · Priciest 25%
P/S (TTM) 4.87× · Priciest 25%
P/FCF 57.4× · Priciest 25%
EV/EBITDA 79.0× · Priciest 25%
PEG 10.00× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)64 · sector 30
PAST (return on equity)9 · sector 26
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $405.18 $348.72 −14%
EssilorLuxottica Société anonyme EL €143.90 €158.29 +10%
Becton, Dickinson and Company BDX $183.82 $104.73 −43%
Medline Inc MDLN $34.70 $29.06 −16%
Alcon Inc ALC $64.47 $40.13 −38%
West Pharmaceutical Services, Inc WST $375.65 $137.81 −63%
Sartorius Stedim Biotech S.A DIM €212.40 €54.82 −74%
Straumann Holding STMN CHF 97.48 CHF 45.50 −53%
Sartorius Aktiengesellschaft SRT €206.50 €42.05 −80%
Solventum Corporation SOLV $89.50 $134.36 +50%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AtriCure, Inc. · Fair Value
$20.85 −64%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "AtriCure, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ATRC

Frequently asked questions

Is AtriCure, Inc. (ATRC) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $20.85 versus a price of $58.05, about −64% upside (overvalued).
What is the fair value of ATRC?
Our model-based fair value for AtriCure, Inc. is $20.85 (as of Sep 27, 2026), built from audited fundamentals. The current price: $58.05.
What is the quality score of ATRC?
AtriCure, Inc. has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AtriCure, Inc. (ATRC)?
Our model-based price target is the fair value of $20.85 (as of Sep 27, 2026) from 11 valuation models. Cautious scenario $13.31, optimistic scenario $35.07. It is a calculation from audited fundamentals, not an analyst target.
What is the AtriCure, Inc. stock forecast for 2026?
Our models put fair value at $20.85, about −64% upside versus a price of $58.05 (overvalued). Cautious scenario $13.31, optimistic scenario $35.07. The calculation is refreshed regularly with new filings.
What is the revenue of AtriCure, Inc. (ATRC)?
AtriCure, Inc. reported trailing-twelve-month revenue of about $570M (latest available figure, as of Sep 27, 2026).
What growth is priced into AtriCure, Inc. (ATRC)?
For today's price to be fair in a discounted-cash-flow model, AtriCure, Inc. would have to grow free cash flow by +30.7 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.0 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of ATRC use?
Our models discount AtriCure, Inc. at 10.3 %: a base by market capitalisation (mid), damped by beta 1.23, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AtriCure, Inc. that is +30.7 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has AtriCure, Inc. (ATRC) delivered so far?
Over the past 5 years revenue at AtriCure, Inc. grew +21.0 % a year. The price currently implies +30.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AtriCure, Inc. (ATRC) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into AtriCure, Inc. (+30.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AtriCure, Inc. (ATRC)?
The free-cash-flow yield on the price is 1.74 %: that much free cash flow AtriCure, Inc. produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AtriCure, Inc. (ATRC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AtriCure, Inc. it is $20.85 per share (as of Sep 27, 2026), against a price of $58.05. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is AtriCure, Inc. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, ATRC trades above its calculated fair value: price $58.05, fair value $20.85, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATRC?
No. The price is what the market pays today ($58.05); the fair value is what the company's own numbers justify ($20.85). For AtriCure, Inc. the two are $37.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is AtriCure, Inc. worth?
The market values AtriCure, Inc. at about $2.8B (market capitalisation, as of Sep 27, 2026). Per share that is $58.05; our models calculate a fair value of $20.85 per share.
What do the bullish and bearish scenarios say about ATRC?
Our models span a range for AtriCure, Inc.: cautious scenario $13.31, base $20.85, optimistic $35.07 per share (as of Sep 27, 2026, price $58.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ATRC?
AtriCure, Inc. trades at a price-to-earnings ratio of 276.4 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $20.85 is built from several models across several years. Other multiples: PEG 10.0, P/B 5.6, P/S 4.9, EV/EBITDA 79.0.
What is the PEG ratio of ATRC?
The PEG ratio of AtriCure, Inc. is 10.00 (P/E divided by earnings growth, as of Sep 27, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of AtriCure, Inc. (ATRC)?
Balance-sheet figures for AtriCure, Inc. (as of Sep 27, 2026): return on equity 2.2%, debt of 0.13 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is ATRC from its 52-week high?
AtriCure, Inc. trades at $58.05, about 4% below its 52-week high of $60.77 and 124% above the low of $25.86 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of $20.85 is for.
Which stocks are comparable to AtriCure, Inc.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AtriCure, Inc. stock attractive at the current price?
The data as of Sep 27, 2026: price $58.05, calculated fair value $20.85 (−64%), Quality Score 69/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATRC calculated?
We run AtriCure, Inc. through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $20.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. AtriCure, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AtriCure, Inc. (ATRC)?
The closing price on Sep 29, 2026 was $58.05. Our model-based fair value is $20.85, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AtriCure, Inc. right now?
The price sits above even our optimistic bull case ($35.07). The favourable scenario is already priced in. The model range is unusually wide ($13.31 to $35.07). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of AtriCure, Inc.

How large is the market capitalisation of AtriCure, Inc. (ATRC)?
The market capitalisation of AtriCure, Inc. is $2.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AtriCure, Inc. (ATRC)?
The price-to-sales ratio of AtriCure, Inc. is 3.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AtriCure, Inc. (ATRC)?
Earnings per share at AtriCure, Inc. are $0.2100 (price ÷ EPS = P/E 276.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of AtriCure, Inc. (ATRC)?
The net margin of AtriCure, Inc. is −2.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AtriCure, Inc. (ATRC)?
The return on equity (ROE) of AtriCure, Inc. is 2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AtriCure, Inc. (ATRC)?
On an EBIT basis the return on assets of AtriCure, Inc. is −2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AtriCure, Inc. (ATRC)?
The operating margin of AtriCure, Inc. is 6.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AtriCure, Inc. (ATRC)?
Revenue at AtriCure, Inc. is growing +12.8% versus a year earlier (3y avg +17.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does AtriCure, Inc. (ATRC) hold?
AtriCure, Inc. holds more cash than debt, $79.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AtriCure, Inc. in the live analysis

One click puts AtriCure, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.